Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 521

1.

Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.

Romero JR.

Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S46-54.

PMID:
12671452
[PubMed - indexed for MEDLINE]
2.

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, Calcagno JA, Eki C, Harris KA, Joyave J, McFarland K, Protter P, Sullivan M, Stanford A, Lovett N, Ortiz M, Rojas S, Cyrus S, Cyrus J, Cohen S, Buchin D, Riordan L, Zuniga M, Shah R, Minard C, Quintin A, Douglas G, van Houten J, Freutner S, Chartrand S, Nowatzke P, Romero J, Rhodes T, Benoit M, Walter E, Walker L, DeBonnett L, Cross M, Free T, Martin S, Shank K, Guedes B, Atkinson LA, Halpin GJ, Rouse K, Hand I, Geiss D, Marshall JR, Burleson L, Boland J, Seybold K, Hunter V, Unfer S, Schmucker J, Gley M, Marcus M, Thompson P, Milla P, Young C, Zanni R, Zinno V, Fetter-Zarzeka A, Busey A, Sokunbi MA, Airington S, Richard N, Muraligopal V, Lewis S, Weber FT, Giordano BP, Linehan D, Roach J, Davis R, Rzepka AA, Booth T, Smeltzer D, Walsh J, Arispe E, Rowley R, Bolling C, Botts T, Haskett K, Raby D, Batiz E, Gelfand A, Farrell L, Butler S, Colby L, Schochet P, Bentler J, Hirsch D, Wilkinson L, Aaronson A, Bennett E, Wingate J, Quinn D, Komendowski K, Deckard M, Frogel M, Nerwen C, Copenhaver S, Prater M, Wolsztein J, Mackey K, Benbow M, Naranjo M, Hensley S, Hayes C, Sadeghi H, Lawson SM, McCall M, Combs K, Ledbetter J, Sarnosky K, Swafford C, Speer M, Barton WJ, Mink JW, Lemm D, Hudak M, Case E, Rowen J, Fuentes S, Pane C, Richardson L, Chavarria C, Cassino D, Ghaffari K, Carroll C, Lee H, Guclu L, Johnson C, Blum V, Boron ML, Sorrentino M, Hirsch RL, Van Veldhuisen PC, Smith C; Palivizumab Outcomes Registry Study Group.

Pediatr Pulmonol. 2003 Jun;35(6):484-9.

PMID:
12746948
[PubMed - indexed for MEDLINE]
3.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
[PubMed - indexed for MEDLINE]
4.

Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.

Carbonell-Estrany X.

Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S55-7; discussion S57.

PMID:
12671453
[PubMed - indexed for MEDLINE]
5.

A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ.

J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. Review.

PMID:
20131495
[PubMed - indexed for MEDLINE]
Free Article
6.

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.

Wang D, Bayliss S, Meads C.

Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124. doi: 10.3310/hta15050. Review.

PMID:
21281564
[PubMed - indexed for MEDLINE]
Free Article
7.

Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.

Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators.

Pediatr Infect Dis J. 2002 Jun;21(6):512-8.

PMID:
12182374
[PubMed - indexed for MEDLINE]
8.

Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.

Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.

J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.

PMID:
20044843
[PubMed - indexed for MEDLINE]
Free Article
9.

Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.

Simoes EA, Carbonell-Estrany X.

Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S13-8; discussion S18-20.

PMID:
12671448
[PubMed - indexed for MEDLINE]
10.

Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.

Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J; Palivizumab Outcomes Registry Group.

Pediatr Infect Dis J. 2008 Oct;27(10):870-3. doi: 10.1097/INF.0b013e318174e0c4.

PMID:
18776822
[PubMed - indexed for MEDLINE]
11.

Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.

Diehl JL, Daw JR, Coley KC, Rayburg R.

J Manag Care Pharm. 2010 Jan-Feb;16(1):23-31.

PMID:
20044844
[PubMed - indexed for MEDLINE]
Free Article
13.

Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.

Arch Dis Child Fetal Neonatal Ed. 2005 Jan;90(1):F64-8.

PMID:
15613580
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.

Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs.

Pediatr Pulmonol. 2002 Sep;34(3):181-8.

PMID:
12203846
[PubMed - indexed for MEDLINE]
15.

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.

Sorrentino M, Powers T.

Pediatr Infect Dis J. 2000 Nov;19(11):1068-71.

PMID:
11099087
[PubMed - indexed for MEDLINE]
16.

CARESS: the Canadian registry of palivizumab.

Mitchell I, Paes BA, Li A, Lanctôt KL; CARESS investigators.

Pediatr Infect Dis J. 2011 Aug;30(8):651-5. doi: 10.1097/INF.0b013e31821146f7.

PMID:
21343842
[PubMed - indexed for MEDLINE]
17.

Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.

Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group.

J Perinatol. 2008 Jul;28(7):511-7. doi: 10.1038/jp.2008.28. Epub 2008 Mar 27.

PMID:
18368063
[PubMed - indexed for MEDLINE]
18.

Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.

Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2004 Sep;23(9):815-20.

PMID:
15361718
[PubMed - indexed for MEDLINE]
19.

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.

Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.

Turk J Pediatr. 2012 Jul-Aug;54(4):344-51.

PMID:
23692714
[PubMed - indexed for MEDLINE]
Free Article
20.

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).

Paes B, Mitchell I, Li A, Lanctôt KL; CARESS Investigators.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2703-11. Epub 2012 May 1.

PMID:
22546928
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk